Dionne Bell
Family · Baton Rouge, LANPI 1588006431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,561 of the $24,153 with a category attached, or 64.4%. Gilead accounts for 93.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $11,861, more than ten times the $491 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $135.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$23K
- Viiv Healthcare Company$528
- Johnson & Johnson$264
- Merck$213
- Janssen Products, LP$198
- Napo Pharmaceuticals Inc$120
- plus $229 from 6 others
Across 2 payments — averaging $470.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$940
What the payments were for
- Speaking & faculty fees$15,56164%
- Travel & lodging$4,78720%
- Food & beverage$3,57815%
- Education$2261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 101 | $22,601 |
| Viiv Healthcare Company | 36 | $528 |
| Johnson & Johnson(2 entities) | 13 | $264 |
| Merck | 10 | $213 |
| Janssen Products, LP | 2 | $198 |
| Napo Pharmaceuticals Inc | 6 | $120 |
| Theratechnologies Inc. | 4 | $84 |
| Dexcom, Inc. | 1 | $61 |
| Exact Sciences | 2 | $37 |
| GSK | 1 | $23 |
| Novartis | 1 | $14 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$17,912
How this compares
$24,153 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 154 | $602,358 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 51 | $190,457 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 46 | $153,879 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 33 | $150,004 |
| DovatoDolutegravir Sodium/Lamivudine | 51 | $144,413 |
| TivicayDolutegravir Sodium | 43 | $113,368 |
| DescovyEmtricitabine/Tenofov Alafenam | 41 | $80,678 |
| JulucaDolutegravir/Rilpivirine | 21 | $71,876 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $71,821 |
| CabenuvaCabotegravir/Rilpivirine | 22 | $69,356 |
| TrulicityDulaglutide | 41 | $47,627 |
| PifeltroDoravirine | 26 | $44,546 |
| OzempicSemaglutide | 33 | $31,378 |
| PrezcobixDarunavir/Cobicistat | 11 | $20,111 |
| JardianceEmpagliflozin | 21 | $19,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $22,601 | $754,857213 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Juluca, Cabenuva | $528 | $589,471188 claims |
| Janssen Products, LPSymtuza | $198 | $150,00433 claims |
| MerckPifeltro, Januvia | $213 | $57,94842 claims |
| Lilly USA, LLCTrulicity | $11 | $47,62741 claims |
| Johnson & JohnsonPrezcobix | $264 | $20,11111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Baton Rouge
- Elidia DewittBaton Rouge$108K
- Ghenet GhebretatiosBaton Rouge$91K
- Heather SullivanBaton Rouge$32K
- Randee KidderBaton Rouge$30K
- Jennifer LittleBaton Rouge$21K
- Tracy ParkerBaton Rouge$19K
- Kristen VillarBaton Rouge$18K
- Sharon JacksonBaton Rouge$15K
- Gloria MarchandBaton Rouge$14K
- Stephanie ThomasBaton Rouge$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.